AU2008226947B2 - Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof - Google Patents

Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof Download PDF

Info

Publication number
AU2008226947B2
AU2008226947B2 AU2008226947A AU2008226947A AU2008226947B2 AU 2008226947 B2 AU2008226947 B2 AU 2008226947B2 AU 2008226947 A AU2008226947 A AU 2008226947A AU 2008226947 A AU2008226947 A AU 2008226947A AU 2008226947 B2 AU2008226947 B2 AU 2008226947B2
Authority
AU
Australia
Prior art keywords
aldh2
compound
substituted
individual
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008226947A
Other languages
English (en)
Other versions
AU2008226947A1 (en
Inventor
Che-Hong Chen
Daria Mochly-Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2008226947A1 publication Critical patent/AU2008226947A1/en
Application granted granted Critical
Publication of AU2008226947B2 publication Critical patent/AU2008226947B2/en
Priority to AU2014250605A priority Critical patent/AU2014250605A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008226947A 2007-03-08 2008-03-07 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof Ceased AU2008226947B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014250605A AU2014250605A1 (en) 2007-03-08 2014-10-14 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90596307P 2007-03-08 2007-03-08
US60/905,963 2007-03-08
PCT/US2008/003092 WO2008112164A2 (en) 2007-03-08 2008-03-07 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014250605A Division AU2014250605A1 (en) 2007-03-08 2014-10-14 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2008226947A1 AU2008226947A1 (en) 2008-09-18
AU2008226947B2 true AU2008226947B2 (en) 2014-07-17

Family

ID=39760277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008226947A Ceased AU2008226947B2 (en) 2007-03-08 2008-03-07 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Country Status (8)

Country Link
US (3) US20110105602A2 (https=)
EP (1) EP2126574B1 (https=)
JP (2) JP2010523476A (https=)
KR (1) KR20090117950A (https=)
CN (1) CN101669030B (https=)
AU (1) AU2008226947B2 (https=)
CA (1) CA2679882C (https=)
WO (1) WO2008112164A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090117950A (ko) 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR20110082180A (ko) * 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
EP2651412A4 (en) * 2010-12-14 2014-08-13 Beth Israel Hospital ANDROGEN RECEPTOR AND HER APPLICATION PROCEDURES
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
US9545393B2 (en) * 2012-08-24 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating pain
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
CN103191103A (zh) * 2013-04-15 2013-07-10 中南大学 乙醛脱氢酶激活物alda-1的合成方法及其用途
CN103923077B (zh) * 2013-07-05 2016-03-02 高尔医药科技(上海)有限公司 两种乙醛脱氢酶激动剂、其制备方法及用途
JP6261278B2 (ja) * 2013-10-16 2018-01-17 国立大学法人広島大学 アルデヒドデヒドロゲナーゼの活性を増強するための医薬組成物
WO2015084731A1 (en) * 2013-12-02 2015-06-11 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase inhibitors and methods of use thereof
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
FR3054564B1 (fr) * 2016-07-28 2018-08-31 Advanced Biodesign Substrat specifique d'une isoenzyme de l'aldh
WO2019098288A1 (ja) * 2017-11-15 2019-05-23 学校法人 慶應義塾 抗腫瘍剤及び配合剤
CA3085992A1 (en) * 2018-01-31 2019-08-08 Eisai R&D Management Co., Ltd. Aldh2 activator
CN114149386A (zh) * 2018-06-04 2022-03-08 中国人民解放军第二军医大学 芳基戊二烯酰胺类醛脱氢酶抑制剂、其合成方法及用途
CN111909138A (zh) * 2019-05-09 2020-11-10 上海仕谱生物科技有限公司 抑制tdg活性的化合物
TW202110437A (zh) * 2019-05-23 2021-03-16 美商希諾瓦有限責任公司 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法
WO2022092310A1 (ja) 2020-11-02 2022-05-05 株式会社アークメディスン 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬
KR20250005979A (ko) 2022-04-22 2025-01-10 앨커메디신, 인크. 화합물, 알데히드데히드로게나아제2 활성화제, 의약 조성물, 그리고 치료 및/또는 예방약

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20050215548A1 (en) * 2002-07-05 2005-09-29 Cyclacel Limited Bisarylsulfonamide compounds and their use in cancer therapy

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2319808A (en) 1939-08-31 1943-05-25 Squibb & Sons Inc Sterol derivatives and process for producing same
JPH01203351A (ja) 1988-02-05 1989-08-16 Mitsui Petrochem Ind Ltd １，４−ジヒドロキシナフタレン誘導体および医薬
JPH023351A (ja) 1988-06-16 1990-01-08 Oki Electric Ind Co Ltd 印刷装置
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
JPH03184973A (ja) 1989-12-14 1991-08-12 Rooman Kogyo:Kk 放射線障害防護剤
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4201047A1 (de) * 1992-01-17 1993-07-22 Bayer Ag Substituierte isoxazolcarbonsaeureamide
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP2994182B2 (ja) * 1992-07-23 1999-12-27 石原産業株式会社 アミド系化合物又はその塩、それらの製造方法及びそれらを含有する有害動物防除剤
JP3833281B2 (ja) 1995-02-03 2006-10-11 日本曹達株式会社 ２，６−ジクロロイソニコチン酸ベンジルアミド誘導体及び植物病害防除剤
PT1019385E (pt) 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
BR9813331A (pt) 1997-10-31 2000-08-22 Aventis Pharma Ltd Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina
AU1832099A (en) 1997-12-22 1999-07-12 Eli Lilly And Company Catalyst and method for amide formation
US6384080B1 (en) * 1998-04-20 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6780883B2 (en) 1998-11-05 2004-08-24 Warner-Lambert Company Amide inhibitors of microsomal triglyceride transfer protein
ATE276241T1 (de) 1998-11-25 2004-10-15 Yissum Res Dev Co Antioxidationsmittel
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
EP1402026A2 (en) 2000-04-18 2004-03-31 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US7141590B2 (en) 2000-12-29 2006-11-28 Ucb Sa Pharmaceutical uses and synthesis of nicotinanilide-N-oxides
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6678516B2 (en) 2001-05-21 2004-01-13 Nokia Corporation Method, system, and apparatus for providing services in a privacy enabled mobile and Ubicom environment
JP4448902B2 (ja) 2001-06-08 2010-04-14 株式会社医薬分子設計研究所 スルホンアミド誘導体
JPWO2003030937A1 (ja) * 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030100034A1 (en) 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
PY0300568A (es) 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
JP4595059B2 (ja) 2002-04-18 2010-12-08 株式会社医薬分子設計研究所 アミド誘導体
CN1732161A (zh) 2002-09-06 2006-02-08 艾伦药物公司 1,3－二氨基－2－羟基丙烷前体药物衍生物
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4359754B2 (ja) 2003-07-03 2009-11-04 三菱瓦斯化学株式会社 基板の洗浄剤
WO2005007889A1 (en) 2003-07-21 2005-01-27 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
WO2005011561A2 (en) 2003-08-04 2005-02-10 Labcoat, Ltd. Stent coating apparatus and method
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
FR2861074B1 (fr) 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
WO2005057213A1 (en) 2003-12-09 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2
WO2005084392A2 (en) * 2004-03-03 2005-09-15 Convivia 4-methylpyrazole formulations for inhibiting ethanol intolerance
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
CN1749415A (zh) * 2004-09-15 2006-03-22 上海人类基因组研究中心 硝酸甘油治疗急性心绞痛疗效检测方法和试剂盒
US7456194B2 (en) 2004-11-12 2008-11-25 Bristol-Myers Squibb Company Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
NZ566136A (en) 2005-09-23 2010-04-30 Pfizer Prod Inc Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
EP2001851A2 (en) 2006-03-28 2008-12-17 Novartis AG Amide derivatives and their application for the treament of g protein related diseases
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20080003585A1 (en) 2006-06-29 2008-01-03 Bio-Rad Laboratories, Inc., A Corporation Of The State Of Delaware Purification and amplification of nucleic acids in a microfluidic device
EP2046769A2 (en) 2006-07-27 2009-04-15 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US8927715B2 (en) 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
DE602006021591D1 (de) 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
WO2008103354A2 (en) 2007-02-20 2008-08-28 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
US8410142B2 (en) * 2007-03-02 2013-04-02 Merck Sharp & Dohme Corp. Bipyridine carboxamide orexin receptor antagonists
KR20090117950A (ko) 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009253812A1 (en) 2008-06-04 2009-12-10 Ambrilia Biopharma Inc. HIV integrase inhibitors from pyridoxine
EP2307379A2 (en) 2008-06-27 2011-04-13 Novartis AG Organic compounds
EP2337563B1 (en) * 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR20110082180A (ko) * 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20050215548A1 (en) * 2002-07-05 2005-09-29 Cyclacel Limited Bisarylsulfonamide compounds and their use in cancer therapy
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Borgna, P. et al "Preparation and Study of the Phytotoxicity Aof N-arylalkyl Substituted Amides. I. Benzylamides", Farmaco Sci., 1977, Vol. 32, No. 11, pages 813-826 *

Also Published As

Publication number Publication date
US20120010248A1 (en) 2012-01-12
CA2679882A1 (en) 2008-09-18
JP2010523476A (ja) 2010-07-15
US9102651B2 (en) 2015-08-11
EP2126574B1 (en) 2015-12-23
WO2008112164A2 (en) 2008-09-18
US20150105456A1 (en) 2015-04-16
EP2126574A4 (en) 2012-02-22
CN101669030A (zh) 2010-03-10
EP2126574A2 (en) 2009-12-02
JP2015061836A (ja) 2015-04-02
AU2008226947A1 (en) 2008-09-18
CN101669030B (zh) 2016-01-13
US20090082431A1 (en) 2009-03-26
WO2008112164A3 (en) 2008-11-13
US20110105602A2 (en) 2011-05-05
US9315484B2 (en) 2016-04-19
CA2679882C (en) 2015-12-29
KR20090117950A (ko) 2009-11-16

Similar Documents

Publication Publication Date Title
AU2008226947B2 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US8772295B2 (en) Modulators of aldehyde dehydrogenase and methods of use thereof
EP2337563B1 (en) Modulators of aldehyde dehydrogenase activity and methods of use thereof
US10227304B2 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
AU2014250605A1 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2015084731A1 (en) Aldehyde dehydrogenase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired